Search Results
Your search for The ASCO,The ASCO matches 21115 pages
Showing 9051 - 9100ASCO Welcomes 2019–2020 Leadership Development Program Participants, Education Scholars
ASCO is pleased to announce the 2019–2020 participants in its Leadership Development Program and Education Scholars Program. Leadership Development Program The ASCO Leadership Development Program, which began in 2009, is a year-long program designed to train future leaders in oncology by supporting ...
New ASCO Ethical Framework for Including Research Biopsies in Clinical Trials
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials. The framework, published in a statement in the Journal of Clinical Oncology on July 25, provides guidance on when to include optional and mandatory biopsies based on both participant ...
2020 Fee Schedule Proposal Outlines E&M Code and MIPS Changes
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B payment policies, including proposals related to the Quality Payment Program (QPP). At the same time, CMS released...
Apply by September 25 to ASCO’s Health Policy Leadership Development Program
Develop expertise in health policy, advocacy, and grassroots activity while learning valuable leadership skills—applications are open through September 25 for the 2020–2021 cycle of ASCO’s Health Policy Leadership Development Program. Oncologists have an important role to play in shaping the...
Sita Kugel, PhD, Receives Grant to Study Aggressive Type of Pancreatic Cancer
The deadly nature of most pancreatic tumors is well known, with less than 10% of patients with pancreatic ductal adenocarcinoma estimated to survive 5 years after diagnosis. Recent molecular analyses of pancreatic ductal adenocarcinoma have shown that a patient’s prognosis changes depending on the...
Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD, Receive Endowed Chairs at Fred Hutchinson Cancer Research Center
Two researchers at the Fred Hutchinson Cancer Research Center in Seattle were recently awarded endowed chairs: Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD. Raisbeck Endowed Chair for Collaborative Research Dr. Davidson was awarded the Raisbeck Endowed Chair for Collaborative Research at Fred ...
Primary Central Nervous System Lymphoma: Striving for a Curative Therapy
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established. In light of recent insights into its pathophysiology and the emergence of novel approaches, The ASCO Post asked Tracy T. Batchelor, MD, a specialist in...
CureMD Oncology Integrates NCCN Templates
The National Comprehensive Cancer Network® (NCCN®) is collaborating with CureMD to integrate the NCCN Chemotherapy Order Templates into the CureMD Oncology electronic health records. This collaboration is intended to allow for point-of-care access to treatment recommendations and order templates...
David I. Sternberg, MD, Joins Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute has announced that thoracic surgeon David I. Sternberg, MD, has joined its medical team. Board-certified in general and cardiothoracic surgery, and specialized in minimally invasive chest surgery, Dr. Sternberg will serve on Karmanos’ Thoracic Oncology...
Northern California Prostate Cancer Center Joins U.S. Oncology Network
The Northern California Prostate Cancer Center, an independent oncology practice serving patients with cancer throughout Santa Clara County, has joined the U.S. Oncology Network. The practice, which opened in 2009, was the first prostate-only radiation treatment center in California to obtain a...
$1 Million Gift for Epithelioid Hemangioendothelioma Research
The Epithelioid Hemangioendothelioma (EHE) Foundation and Cleveland Clinic recently received a $1 million gift from the Margie and Robert E. Petersen Foundation. The money will support EHE research conducted by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine ...
IU Simon Cancer Center Earns NCI’s Comprehensive Cancer Center Designation
The Indiana University Melvin and Bren Simon Cancer Center (IU Simon Cancer Center) has achieved the highest recognition from the National Cancer Institute (NCI): Comprehensive Cancer Center. With this federal designation signifying research excellence, it becomes the only NCI-designated...
NCI Community Oncology Research Program Expands to More Sites
The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to 7 research hubs, these NCI grants went to 32 community...
Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse...
FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC
On August 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...
FDA Approves Fedratinib for Treatment of Myelofibrosis
On August 16, the U.S. Food and Drug Administration (FDA) approved the Janus kinase 2 (JAK2) inhibitor fedratinib (Inrebic) for the treatment of adults with intermediate-2 or high-risk primary or secondary (postpolycythemia vera or postessential thrombocythemia) myelofibrosis. “Prior to [this...
SITC Publishes First Clinical Immunotherapy Guidelines for Treatment of Head/Neck Squamous Cell Carcinoma
The Society for Immunotherapy of Cancer (SITC) has published the first clinical immunotherapy guidelines for squamous cell carcinoma of the head and neck, providing oncologists and other advanced practice providers with a clinical roadmap to treating this disease with immunotherapies approved in...
Karen M. Winkfield, MD, PhD, on Policy and Business Solutions to Address Disparities in Cancer Care
Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in addressing inequities in access to care, and what local institutions can do to improve the situation.
The Mark Foundation Awards $6 Million Grant for Lung Cancer Research
The Mark Foundation for Cancer Research has awarded a 3-year $6 million grant to support a new phase of discovery for a team of investigators developing, optimizing, and integrating targeted therapies and immunotherapies to improve outcomes for patients with the most common—and most difficult to...
Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value
Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidance for patients with cancer.
Hey Siri, Should I Get a Medical Degree?
I received a coffee mug from a physician colleague some years ago with the tag line: “Please do not confuse your Google search with my Medical Degree.” Physicians of all stripes and colors can relate to the agony of debunking a “Dr. Google” diagnosis. However, in a fast-evolving health-care...
How Patient Advocacy Is Integral to High-Quality Oncology Care
Karen M. Winkfield, MD, PhD, has made patient advocacy—with a specific emphasis on health equity and access to high-quality care—front and center of her oncology practice since she completed her residency at the Harvard Radiation Oncology Program in Boston, where she noticed that most of the...
WCLC 2019: Safety and Toxicity of AMG 510 for KRAS G12C–Mutated, Advanced NSCLC
In a clinical trial testing the toxicity of a KRAS inhibitor, the treatment demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. The research was presented by Govindan et al at the...
WCLC 2019: First-Line Nivolumab/Ipilimumab in Special Populations With NSCLC
First-line therapy consisting of nivolumab plus ipilimumab showed a consistent safety profile in special populations with advanced non–small cell lung cancer (NSCLC), according to research presented by Fabrice Barlesi, MD, PhD, of Aix-Marseille University, Assistance Publique Hôpitaux de Marseille...
WCLC 2019: Two Studies Show Tumor Mutational Burden Not Associated With Pembrolizumab Efficacy in NSCLC
At the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC), two presentations showed that tumor mutational burden is not associated with the efficacy of pembrolizumab in combination with chemotherapy in patients with non–small cell lung cancer...
2019 Quality Care: Intervention to Improve Rates of Resident Advanced Care Planning Documentation
In a single-center study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Switzer et al found that an intervention consisting of a resident training module and use of a best practice alert (BPA) in electronic medical records (EMRs)...
2019 Quality Care: Improving Documentation of Pain and Constipation Assessment and Management
In a study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Chineke et al found that a Quality Oncology Practice Initiative (QOPI) initiated in collaboration with ASCO at the Georgia Cancer Center for Excellence (GCCE) at Grady Health...
2019 Quality Care: Improving Caregiver Identification and Support in a Gynecologic Oncology Practice
In a study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Campbell et al found that an ASCO Quality Training Program Project—the Plan-Do-Study-Act (PDSA) initiative—resulted in improvement in primary caregiver identification and...
Real-Time ctDNA Evaluation in Patients With Hepatocellular Carcinoma
In a study published in the Journal of Gastrointestinal Oncology, Mody et al described results from patients with hepatocellular carcinoma undergoing circulating tumor DNA (ctDNA) testing in a real-time clinical context. The authors wrote, “[ctDNA assessment] holds incredible promise for early...
FDA Pipeline: Fast Track Designation in Myelodysplastic Syndrome and AML, Plus Multiple Breakthrough Designations
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to magrolimab in myelodysplastic syndrome and acute myeloid leukemia (AML). The agency also granted Breakthrough Therapy designations in lung cancer and desmoid tumors, as well as Breakthrough Device designations...
Light Intervention for Cancer-Related Fatigue, Depression, and Sleep Disturbance
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Cancer and its treatments are associated with severe fatigue, depression, ...
USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk
In a statement published in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended that clinicians offer to prescribe risk-reducing medications to women who are at an increased risk of breast cancer and at low risk of adverse events related to medications. However, the Task Force...
First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor...
Does PTSD Increase the Risk of Developing Ovarian Cancer?
Women who experienced six or more symptoms of posttraumatic stress disorder (PTSD) at some point in life had a twofold greater risk of developing ovarian cancer compared with women who never experienced any PTSD symptoms. These findings were published by Roberts et al in Cancer Research. The...
ASTRO Guideline on Use of Radiation Therapy for Patients With Pancreatic Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the optimal dosing, timing, and...
Pregnancy Appears Safe After Treatment for Breast Cancer in Patients With BRCA Mutations
Pregnancy after breast cancer appears to be safe in patients with germline BRCA mutations—and particularly among those with BRCA1 mutations—according to new research. Limited data are available on the safety of pregnancy and reproductive outcomes in patients with breast cancer and BRCA mutations,...
ASCO and MASCC/ISOO Release a Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw
ASCO and the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) have published a clinical practice guideline on medication-related osteonecrosis of the jaw in the Journal of Clinical Oncology.1 The guideline outlines the latest recommendations ...
New Report Finds Cancer Drugs Account for Over a Quarter of All New Drug Approvals in the United States
Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010—an increase from the 4% share they occupied in the 1980s, a newly completed analysis summarized in the most recent issue of the Tufts CSDD Impact Report. From 1980 through 2018, the U.S. Food and Drug...
Association Between Postdischarge Bleeding in Patients With Acute Coronary Syndrome and Subsequent Cancer Diagnosis
Bleeding during the first 6 months after discharge from the hospital for acute coronary syndrome may be linked to subsequent cancer diagnosis, according to research presented by Muñoz Pousa et al at the European Society of Cardiology Congress 2019 (Abstract P677). “Our results suggest that patients ...
ASCO Expands Therapeutic Options for Venous Thromboembolism Prophylaxis in Patients With Cancer
ASCO has updated its recommendations for the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. “The recommendations were last updated in 2015, but since then, new, significant publications have emerged, which prompted this update,” said Nigel S. Key, MBChB, of the...
Is It Time to Intervene in Smoldering Myeloma?
Early intervention in smoldering multiple myeloma prevents progression to symptomatic disease and should be strongly considered for patients meeting new criteria for high risk, according to Sagar Lonial, MD, Professor and Chair of Hematology and Medical Oncology and the Anne and Bernard Gray...
2019 Quality Care: Socioeconomic Deprivation and Outcomes in Cancer Clinical Trials
In a study to be presented by Unger et al at the 2019 ASCO Quality Care Symposium, researchers found patients living in socioeconomically deprived areas were more likely to experience worse survival in cancer clinical trials, even after adjustments for race and insurance (Abstract 162). Methods...
2019 Quality Care: End-of-Life Care in Western Washington State vs Alberta, Canada
In a study to be presented by Khaki et al at the 2019 ASCO Quality Care Symposium, researchers found more aggressive end-of-life measures—including use of chemotherapy and admissions to the intensive care unit (ICU)—were employed in the last 30 days of life in Western Washington state vs Alberta,...
2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care
Drug costs and requirements for prior authorization of treatment plans pose barriers to cancer treatment and can potentially affect outcomes for many patients, according to two studies that will be presented at the ASCO Quality Care Symposium. The studies respectively examine how the high...
2019 Quality Care: Clinical Trial Enrollment May Be Associated With Reduced Mortality in Patients With Metastatic Lung Cancer
Researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle investigated the relationship between participation in a clinical trial and overall survival in patients with advanced non–small cell lung cancer (NSCLC). Cristina Merkhofer, MD, MHS, will present...
TITAN Trial: Apalutamide Adds to Options for Men With Metastatic Hormone-Sensitive Prostate Cancer
Androgen-deprivation therapy has been, and remains, the standard of care for patients with metastatic prostate cancer. Patients are often surprised to know that was all we would do to control their disease and sometimes asked why they would not get chemotherapy, as for other cancers. I would take...
FDA Recommendation on Duodenoscopes With Disposable Components
The U.S. Food and Drug Administration (FDA) has recommended that duodenoscope manufacturers and health-care facilities transition to different types of duodenoscopes that may pose less risk to patient safety. Specifically, because of challenges with cleaning these devices for reuse and persistent...
Analysis of HPV-Related Cancers Reported From 2012 to 2016
During 2012–2016, an average of approximately 34,800 human papillomavirus (HPV)-associated cancers were reported each year, according to a new study published by Senkomago et al in Morbidity and Mortality Weekly Report. Among the cancers probably caused by HPV, 92% are attributable to the HPV types ...
Study Explores Efficacy of Lower-Dose Olanzapine in Combination With Standard Antiemetic Regimen
Olanzapine at a 5-mg dose, when combined with aprepitant, palonosetron, and dexamethasone, significantly reduced the risk of delayed nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to new research. The study investigators believe this approach may be considered a...
What Role Do Physicians Play in Health Promotion Among Patients With Cancer?
A recent study published by Stump et al in Cancer indicated that certain physicians who care for patients with cancer do not often promote healthy lifestyle changes to cancer survivors, and they may fear that providing such advice would distress or overwhelm patients. The findings are noteworthy...
